News
BOSTON, October 27, 2024 — Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced that new translational data for its receptor-interacting protein kinase 2 (RIPK2) scaffolding inhibitor product candidate, OD-07656, will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held October 25-30, 2024.
Activation of RIPK2 in innate immune cells is linked to multiple aspects of inflammatory bowel disease (IBD) pathogenesis through its role as a signal transducer and amplifier of cytokine production. This presentation will focus on the anti-inflammatory and anti-fibrotic effects of RIPK2 scaffolding inhibition, a proprietary gene signature for RIPK2 activation, RIPK2 as a mechanism of resistance to standard of care therapies, and the additive activity of RIPK2 inhibition with standard of care therapies.
“Odyssey’s presentation represents our ongoing commitment to advancing potentially transformative therapies to treat patients suffering from inflammatory diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “At this year’s ACG, we will share additional data supporting the monotherapy potential of our RIPK2 product candidate, but also its potential as a combination therapy with standard-of-care to deepen responses and address treatment resistance. We are excited by the potential of an innate immune targeted medicine for patients with IBD and look forward to sharing this data with researchers and patients.”
Poster Presentation
Title: Blocking RIPK2 Scaffolding Inhibits Downstream Signaling that Drive Inflammatory Bowel Disease
Poster Number: P4328
Presenting Author: Marta Wlodarska, PhD
Dates: October 29, 2024| 10:30 AM – 4:00 PM ET | Pennsylvania Convention Center, Exhibit Hall E
About Odyssey Therapeutics
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has leveraged the scientific expertise of its team of drug hunters and a comprehensive suite of tools to efficiently build a portfolio of internally discovered product candidates that it believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.
Disclaimer
All statements contained herein other than statements of historical facts are forward-looking statements, including, but not limited to, statements regarding business strategy; the future clinical development, efficacy, safety and therapeutic potential of product candidates; expectations regarding the initiation, design and reporting of data from preclinical studies and clinical trials; expectations regarding regulatory approval of any product candidates; and plans for future operations or other characterizations of future events. In some cases, you can identify forward-looking statements through the use of words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These statements are not guarantees of future performance and involve risks and uncertainties, some of which are beyond our control, and you are cautioned not to place undue reliance on any forward-looking statements.
Media Contact:
Josh George
[email protected]
713-828-1913